A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours
Latest Information Update: 20 Feb 2024
At a glance
- Drugs U3 1784 (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 06 Oct 2017 Status changed from recruiting to discontinued.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 26 Feb 2016 New trial record